Alexandria Real Estate Equities and the Foundation for the National Institutes of Health (FNIH) have completed the design phase of MAP-D, the Multi-Modal Assessment & Phenotyping in Depression initiative, clearing the way for a $70 million-plus public-private effort to find the biological subtypes hiding inside a diagnosis that’s long been treated as one disease. It’s a milestone worth pausing on for a very local reason too: both organizations driving it have deep roots in Maryland’s biotech corridor.
What MAP-D Is Actually Trying to Do
Depression isn’t one thing clinically, even though it gets treated that way. More than 21 million U.S. adults experience a major depressive episode every year, first-line treatments fail roughly 70% of the time, and patients routinely spend months or years cycling through options before finding something that works, if they ever do. The human and economic toll is enormous: depression costs the country more than $380 billion annually, and it’s tied to roughly 50,000 suicide deaths a year in the U.S.
MAP-D is built to attack the root of that problem: there’s currently no reliable way to tell, up front, which patients will respond to which treatment. The initiative will use genomics, brain imaging, digital health data, and patient-reported outcomes, run through custom AI models, to identify distinct biological subtypes of major depressive disorder. With the design phase now complete, the program moves into a three-year pilot backed by $22 million of the total commitment, enrolling more than 300 patients nationally, ages 15 and up, with moderate to severe depression, including overlapping conditions like PTSD, bipolar disorder, anxiety, and substance use. If the pilot delivers, FNIH says the program could expand to a second phase enrolling 2,500-plus patients.
The list of organizations backing it is long: pharmaceutical and biotech partners including AbbVie, Alto Neuroscience, Eli Lilly, Definium Therapeutics, Engrail Therapeutics, Circular Genomics, Cogstate, and Neumarker; federal partners including the National Institute of Mental Health and the FDA; academic contributors from Harvard, Stanford, Cornell, and Columbia; and advocacy groups including the American Psychiatric Association Foundation and NAMI.
Two Maryland Institutions, One Partnership
Here’s the part that makes this feel like a hometown story even though it’s a national initiative. FNIH is headquartered in North Bethesda, Maryland, just down the road from the NIH campus it was chartered to support, and its entire model is built on connecting NIH scientists with industry, academia, and patient groups to tackle problems too big for any one organization.
Alexandria, meanwhile, has been building out its own Maryland footprint for years around that same NIH gravity. Its Alexandria Center for Life Science – Shady Grove Mega Campus in Rockville anchors a cluster of life science real estate specifically positioned to serve companies and researchers working near NIH, and Alexandria has continued expanding that footprint, including leasing moves explicitly aimed at growing NIH’s own presence in the region. So while MAP-D is a national, multi-site study, the two organizations that built the partnership both call the Bethesda-Rockville biotech corridor home turf.
FNIH President and CEO Julie Gerberding, MD, MPH, put the scale of the challenge in plain terms: “Depression is a growing public health issue. It will require long-term, collaborative commitment from many organizations.” FNIH Senior Vice President and Chief Preclinical Officer Steve Hoffmann framed the goal this way: “MAP-D is creating the evidence base needed to move from one-size-fits-all toward precision-driven care.”
Why It’s Worth Watching
Precision medicine has transformed how a lot of cancers and rare diseases get treated by matching patients to therapies based on their underlying biology instead of trial and error. Psychiatry has mostly been left out of that shift, largely because there hasn’t been a large, well-funded, multi-modal dataset built specifically to find those biological patterns in depression. MAP-D is a real attempt to close that gap, and the fact that it’s anchored by two organizations rooted in Maryland’s NIH-adjacent biotech cluster is a good reminder that the region isn’t just leasing lab space to national and global players. It’s actively driving the science, not just hosting it.
